NewLimit Raises $435 Million In Funding Round Valuing Company At $3.1 Billion

NewLimit, a longevity startup co-founded by Brian Armstrong, Blake Byers, and Jacob Kimmel, raised $435 million in a funding round. This investment values the company at $3.1 billion and aligns with increasing investor enthusiasm for drugs aimed at slowing or reversing aging. The company is focused on reversing cellular aging and intends to begin human studies next year for its first drug that targets alcohol-related liver disease.

Summary of transaction details:

• Deal Type: Funding Round
• Transaction Amount: $435,000,000
• Valuation: $3,100,000,000
• Founders: Brian Armstrong, Blake Byers & Jacob Kimmel
• Investors: Founders Fund, Thrive Capital & Lilly Ventures
• Headquarters: San Francisco, California

Jacob Kimmel, who was recently appointed CEO, stated that focusing initially on liver disease is intended as a stepping stone towards broader applications in anti-aging. NewLimit is positioned among a cohort of billionaire-backed longevity ventures pursuing similar rejuvenation science.